Asset Details
Do you wish to reserve the book?
Effect of Hepatitis B and C Virus Infections on The Natural History of Compensated Cirrhosis: A Cohort Study of 297 Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Hepatitis B and C Virus Infections on The Natural History of Compensated Cirrhosis: A Cohort Study of 297 Patients
Do you wish to request the book?
Effect of Hepatitis B and C Virus Infections on The Natural History of Compensated Cirrhosis: A Cohort Study of 297 Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Hepatitis B and C Virus Infections on The Natural History of Compensated Cirrhosis: A Cohort Study of 297 Patients
2002
Overview
The aim of this study was to compare the prognosis of patients with hepatitis B surface antigen(HBsAg) positive and those with antibody to hepatitis C (anti-HCV) positive cirrhosis. This was a retrospective cohort study of 297 untreated Western European patients with compensated viral cirrhosis (Child class A; 161 patients with hepatitis type B and 136 with type C) who were followed for a median period of 6.6 yr. At diagnosis, median age was lower (48 vs 58 yr, respectively) in HBsAg-positive cirrhotic patients. The Kaplan-Meier 5-yr probability of hepatocellular carcinoma (HCC) was 9% and 10% in HBsAg and anti-HCV-positive cirrhotic patients, respectively; the corresponding figures for decompensation unrelated to HCC were 16% and 28% and for survival were 86% and 84%, respectively. After adjustment for clinical and serological differences at baseline, the relative risk (95% CI) for HCC, decompensation and mortality was 1.53 (CI = 0.81–2.89), 0.59 (CI = 0.37–0.94), and 1.44 (CI = 0.85–2.46) respectively, in HBsAg-positive patients compared with anti-HCV-positive cirrhotic patients. Among HBsAg-positive cirrhotic patients, the relative risk for HCC, decompensation, and mortality was 0.89 (CI = 0.30–2.63), 4.05 (CI = 1.09–15.1), and 5.9 (CI = 1.64–21.3), respectively, in HBV-DNA positive (HBeAg positive or negative) compared with HBV-DNA negative (HBeAg negative) patients at entry. Patients with HBV infection may present with cirrhosis about 10 yr earlier than those with HCV infection. HCV infection tends to be associated with a higher risk of decompensation, but these data should take into consideration the heterogeneity of HBV-related cirrhosis in terms of viremia levels and risk of hepatic failure. Survival shows no significant differences according to HBV or HCV etiology in Western European cirrhotic patients.
Publisher
.,Blackwell Publishing,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subject
/ Adult
/ Aged
/ Biological and medical sciences
/ Carcinoma, Hepatocellular - etiology
/ Carcinoma, Hepatocellular - virology
/ Europe
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Hepatitis B Surface Antigens - blood
/ Hepatitis C Antibodies - blood
/ Humans
/ Liver Cirrhosis - complications
/ Liver Cirrhosis - metabolism
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
